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DEAR EDITOR, The group of reticulate pigmentary disorders
includes the rare autosomal dominant Dowling–Degos disease
(DDD) and Galli–Galli disease (GGD; OMIM 179850, 615327
and 615696).1 In light of substantial clinical, histological and
mutational overlap between GGD and DDD, they are considered
to belong to the same entity.2,3 Mutations in KRT5 (encoding
keratin 5) have been associated with GGD/DDD since 2006.2–5
With the development of whole-exome sequencing, mutations
in POFUT1 (encoding protein O-fucosyltransferase 1)6,7 and
POGLUT1 (encoding protein O-glucosyltransferase 1)8 have been
shown to underlie some cases of GGD/DDD. We report muta-
tions in POGLUT1 in three families of European ancestry.
In family 1 the mother presented, aged 75 years, with a
40-year history of reticulate hyperpigmented scaling plaques
on the neck, lateral proximal arms, proximal legs and popliteal
fossae (Fig. 1a, b). Light microscopy revealed epidermal acan-
thosis, hypergranulosis and hyperkeratosis with parakeratosis
and suprabasilar acantholysis (Fig. 1c). Direct DNA sequencing
of KRT5 was negative for mutations. A whole-exome sequenc-
ing approach was taken using DNA from the affected mother
(Appendix S1 and Table S1; see Supporting Information). Dur-
ing this time mutations were reported in POFUT1 and
POGLUT1. A previously reported heterozygous nonsense muta-
tion was identified in POGLUT1, p.Arg218*; c.652C>T, and
confirmed by Sanger sequencing. The mutation was identified
in her affected son but not in two unaffected daughters.
A second family with GGD/DDD, present in two generations,
was also negative for KRT5 mutation. The proband was a 40-
year-old man who progressively developed, starting from ado-
lescence, small red-brown macular and papular crusted lesions
(Fig. 1d). His father had similar clinical features (Fig. 1e). Light
microscopy showed filiform digitate downgrowth of epidermal
rete ridges, presence of small horn cysts, apical acantholysis and
parakeratosis with a moderate dermal inflammatory infiltrate
(Fig. 1f). POFUT1 and POGLUT1 were screened by Sanger
sequencing (Appendix S1). A previously unreported heterozy-
gous missense mutation was identified in POGLUT1, p.Gly170-
Glu; c.509G>A, in the affected father and affected son, but not
in the unaffected mother or unaffected brother (Fig. 2a, b).
p.Gly170 is highly conserved in the encoded enzyme across spe-
cies. In silico prediction tools, MutationTaster (http://www.
mutationtaster.org/) and PolyPhen-2 (http://genetics.bwh.
harvard.edu/pph2/), predict this to be a disease-causing vari-
ant. It is not in the dbSNP (http://www.ncbi.nlm.nih.gov/
SNP/), NHLBI Exome Variant Server (http://evs.gs.washing-
ton.edu/EVS/) or ExAC (http://exac.broadinstitute.org/) data-
bases. No mutations were identified in POFUT1.
A 52-year-old woman, in family 3, presented at age
50 years with a 10-year history of multiple, sometimes itchy,
small red-brown scaly lesions. These started on her legs then
spread onto her forearms with a few lesions on her trunk
(Fig. 1g–j). Her mother had similar lesions. Light microscopy
of different skin biopsies variably showed focal hyperkeratosis,
focal parakeratosis, acantholysis and elongation of rete ridges
with a mild patchy chronic inflammatory infiltrate in the
upper dermis (Fig. 1k). One biopsy showed acantholysis,
(Fig. 1l). Screening of KRT5 and POFUT1 did not yield any
mutations. A heterozygous missense mutation was identified
in POGLUT1, p.Cys286Tyr; c.857G>A, in both affected individ-
uals (Fig. 2c, d). PolyPhen-2 and MutationTaster predict this
previously unreported variant as disease causing; it is not in
the dbSNP, NHLBI Exome Variant Server or ExAC databases.
p.Cys286 is highly conserved across a number of species.
Mutations in POGLUT1 were reported by Basmanav et al.8 in
13 unrelated individuals. The majority were nonsense muta-
tions, but there were also a splice-site and a missense muta-
tion. We identified one previously reported nonsense
mutation, p.Arg218*, and two previously unreported missense
mutations, p.Gly170Glu and p.Cys286Tyr. The p.Arg218*
mutation results in a truncated form of POGLUT1 that lacks
part of the substrate-binding site required for high-affinity
binding of UDP-glucose.8
Using homology modelling, we investigated the effects of
the two missense mutations (Fig. 2e). Gly170 is on a short
helical segment with C-alpha hydrogens directed into a
hydrophobic pocket that likely stabilizes a subdomain, part of
the N-terminal domain. This pocket is about 15 A distant from
the site of catalysis. A mutation to glutamate places a polar
and acidic side chain into this hydrophobic environment. The
result would be potentially destabilizing electrostatic interac-
tions and steric clashes with Val137, Tyr161 and Ile176.
Cys286 is in the C-terminal domain, close to Cys263. The
model strongly suggests that a disulfide bond would be
formed by these two residues. Mutation of Cys286 to tyrosine
would remove the highly stabilizing disulfide bond that holds
together distinct elements of secondary structure, and then,
depending on which side-chain rotamers were adopted, to
clash with Phe278, His282, Leu283, Val260 and Ser288,
which form part of the hydrophobic core of the C-terminal
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Fig 1. Clinical findings. (a, b) Reticulate hyperpigmented scaling plaques on the proximal legs of the proband of family 1. (c) Light microscopy
of three punch biopsies from the proband of family 1 revealed similar findings of filiform digitate downgrowth of the epidermal rete ridges,
presence of small horn cysts, epidermal acanthosis, hypergranulosis, and hyperkeratosis with parakeratosis and suprabasilar acantholysis. (d) Small
red-brown macules and crusted papules widely distributed over the trunk, neck, back, abdomen and limbs of the proband of family 2. The large
body folds, hands and feet, and face were spared. (e) The father of the proband of family 2 had similar clinical features, limited to the neck
region without involvement of the large flexures. (f) Light microscopy shows some apical acantholysis and parakeratosis with a moderate dermal
inflammatory infiltrate. (g–j) The proband of family 3 with multiple small (approximately 5-mm-diameter) red-brown scaly papules, present
predominantly on the legs but also on the forearms with some postinflammatory change from previous lesions. (k) Light microscopy from the
proband of family 3, a medium-power view showing elongation of the rete ridge and modest inflammatory infiltrate. (l) A medium-power view
of a second biopsy from the right anterior thigh. There is an intraepidermal vesicle, as a result of acantholysis of the keratinocytes, some of which
show dyskeratosis. Note the elongation of the rete ridges immediately below the vesicle.
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Wild type POGLUT1, exon 5  POGLUT1 p.Gly170Glu
Wild type POGLUT1, exon 9  POGLUT1 p.Cys286Tyr
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domain. Again, the consequence would be to destabilize the
protein fold at a position about 15 A from the site of catalysis.
These models predict that each missense mutation, p.Gly170-
Glu and p.Cys286Tyr, would compromise enzyme activity due
to a reduction in stability of the protein fold near the active
site.
POGLUT1 adds O-linked glucose to serine residues in epi-
dermal growth factor-like repeats of Notch receptors, and is
an essential regulator of Notch signalling. Loss of Notch1 and
Notch2 in mice results in abnormal pigmentation; these and
other studies suggest that mutations in POGLUT1 resulting in
aberrations in Notch signalling would lead to abnormal pig-
mentation and keratinocyte morphology.9,10
Differences were noted between our cases. In family 2,
lesions were widely scattered over the entire trunk and limbs
(son) and on the neck and upper trunk region (father), rather
than in a reticulated pattern. Similarly, in family 3 there was
no reticulate rash compared with that of family 1. With only
a small number of cases reported it is difficult to draw any
genotype–phenotype correlation.
These findings expand the spectrum of mutations in
POGLUT1 and confirm POGLUT1 as the third candidate gene,
along with KRT5 and POFUT1, to consider in diagnosis of
GGD/DDD.
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Supporting Information
Additional Supporting Information may be found in the online
version of this article at the publisher’s website:
Appendix S1. Supplementary methods.
Fig 2. Mutation analysis and protein modelling. (a) Wild-type POGLUT1 sequence of exon 5 showing nucleotides c.502–516. (b) Equivalent
region as in (a) from the proband of family 2, showing the heterozygous mutation c.509G>A leading to missense mutation p.Gly170Glu. (c)
Wild-type POGLUT1 sequence showing nucleotides c.850–864 of exon 9. (d) Equivalent region as in (c) from the proband of family 3, showing
the heterozygous mutation c.857G>A resulting in missense mutation p.Cys286Tyr. (e) The protein model of human POGLUT1. The enzyme
structure is shown in cartoon format with cylinders (cyan) to represent a-helices, and arrows (purple) b-strands that are linked by coils (brown).
The residues Gly170, Cys263 and Cys286 are depicted in CPK representation coloured N blue, S yellow, O red and C green. The N-terminal
domain consists of residues 1–180. The modelling predicts that each missense mutation, p.Gly170Glu and p.Cys286Tyr, would compromise
enzyme activity due to a reduction in stability of the protein fold near the active site.
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Table S1. POGLUT1 primers for polymerase chain reaction
and sequencing.
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Regional variation of hidradenitis suppurativa
in the Norwegian Patient Registry during a
5-year period may describe professional
awareness of the disease, not changes in
prevalence
DOI: 10.1111/bjd.14990
DEAR EDITOR, Hidradenitis suppurativa (HS) is a distinct skin
disease characterized by well-defined signs, symptoms and a
notorious tendency to recurrence and chronicity.1 Neverthe-
less, considerable uncertainty exists regarding its prevalence.
The prevalence has been estimated over recent decades with a
significant degree of unexplained discrepancy, ranging from
005% to 8% in available studies.2 In general, registry-based
studies tend to indicate lower prevalence rates than reports
based on physician-examined or self-reported data. It may be
suspected that registry data are influenced by local variations
in the healthcare system.
We accessed the Norwegian Patient Registry, which is a
public registry providing basic descriptive data on all patients
treated in public hospitals, policlinics and by practising spe-
cialists under public contract. The registry is based on Interna-
tional Classification of Diseases (ICD)-10 coding and allows
for the comparison of registry-based prevalence estimates of
different diseases for the different health regions of Norway.
Therefore, it offers data generally comparable with data
described in other registry studies.
We investigated possible differences in the number of
patients treated for HS in various Norwegian health regions in
order to explore the variation in prevalence rates. Patients
were identified based on the ICD code for HS (L73.2) and
simple descriptive statistics provided for each region. Data are
shown in Figures 1 and 2.
Two relevant observations could be made based on the data.
Firstly, the prevalence rates varied widely. The number of
cases coded by specialists show large differences between the
Fig 2. Patients diagnosed as L73.2 per year in
the period 2002–2006 in Norway. There was
an increase in the overall number of patients
(white bars, men; light grey bars, women;
dark grey bars, total) registered from 1131
patients to 1677 patients.
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Fig 1. Rate 1/10 000 diagnosed as L73.2
(International Classification of Diseases 10
coding) in 2002 (blue) and 2006 (red) for
the different health authorities of Norway.
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